Use of methylxanthine therapies for the treatment and prevention of apnea of prematurity

Pediatric Drugs

Volumn 16, Issue 2, 2014, Pages 169-177

  Schoen, Katherine ^a   Yu, Tian ^a   Stockmann, Chris ^a   Spigarelli, Michael G ^a   Sherwin, Catherine M T ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CAFFEINE CITRATE; METHYLXANTHINE; THEOPHYLLINE;

COMPARATIVE EFFECTIVENESS; COST CONTROL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; DRUG SAFETY; HUMAN; LONGITUDINAL STUDY; NEWBORN APNEA; OUTCOME ASSESSMENT; PHARMACODYNAMICS; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SECONDARY ANALYSIS; TREATMENT RESPONSE;

APNEA; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CITRATES; DRUG MONITORING; HUMANS; INFANT, PREMATURE; INFANT, PREMATURE, DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THEOPHYLLINE;

EID: 84898417152     PISSN: 11745878     EISSN: 11792019     Source Type: Journal    
DOI: 10.1007/s40272-013-0063-z     Document Type: Review

References (65)

1. Theobald K, Botwinski C, Albanna S, et al. Apnea of prematurity: diagnosis, implications for care, and pharmacologic management. Neonatal Netw. 2000;19(6):17-24.
2. Zhao J, Gonzalez F, Mu D. Apnea of prematurity: from cause to treatment. Eur J Pediatrics. 2011;170(9):1097-105.
3. Alden ER, Mandelkorn T, Woodrum DE, et al. Morbidity and mortality of infants weighing less than 1,000 grams in an intensive care nursery. Pediatrics. 1972;50(1):40-9.
4. Montandon G, Bairam A, Kinkead R. Long-term consequences of neonatal caffeine on ventilation, occurrence of apneas, and hypercapnic chemoreflex in male and female rats. Pediatr Res. 2006;59(4 Pt 1):519-24.
5. Supinski GS, Deal EC Jr, Kelsen SG. The effects of caffeine and theophylline on diaphragm contractility. Am Rev Respir Dis. 1984;130(3):429-33.
6. Aranda JV, Turmen T. Methylxanthines in apnea of prematurity. Clin Perinatol. 1979;6(1):87-108.
7. Aranda JV, Turmen T, Davis J, et al. Effect of caffeine on control of breathing in infantile apnea. J Pediatrcs. 1983;103(6):975-8.
8. Dzhala V, Desfreres L, Melyan Z, et al. Epileptogenic action of caffeine during anoxia in the neonatal rat hippocampus. Ann Neurol. 1999;46(1):95-102.
9. Gu L, Gonzalez FJ, Kalow W, et al. Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. Pharmacogenetics. 1992;2(2):73-7.
10. Kalow W, Tang BK. The use of caffeine for enzyme assays: a critical appraisal. Clin Pharmacol Ther. 1993;53(5):503-14.
11. Carrillo JA, Benitez J. Clinically significant pharmacokinetic interactions between dietary caffeine and medications. Clin Pharmacokinet. 2000;39(2):127-53.
12. Ha HR, Chen J, Freiburghaus AU, et al. Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br J Clin Pharmacol. 1995;39(3):321-6.
13. Robson RA, Miners JO, Matthews AP, et al. Characterisation of theophylline metabolism by human liver microsomes: inhibition and immunochemical studies. Biochem Pharmacol. 1988;37(9):1651-9.
14. Bory C, Baltassat P, Porthault M, et al. Metabolism of theophylline to caffeine in premature newborn infants. J Pediatr. 1979;94(6):988-93.
15. Steer P, Flenady V, Shearman A, et al. High dose caffeine citrate for extubation of preterm infants: a randomised controlled trial. Arch Dis Child Fetal Neonatal Ed. 2004;89(6):F499-503.
16. Tracy MB, Klimek J, Hinder M, et al. Does caffeine impair cerebral oxygenation and blood flow velocity in preterm infants? Acta Paediatr. 2010;99(9):1319-23.
17. Henderson-Smart DJ, Steer PA. Caffeine versus theophylline for apnea in preterm infants. Cochrane Database Syst Rev. 2010;(1):CD000273.
18. Charles BG, Townsend SR, Steer PA, et al. Caffeine citrate treatment for extremely premature infants with apnea: population pharmacokinetics, absolute bioavailability, and implications for therapeutic drug monitoring. Ther Drug Monit. 2008;30(6):709-16.
19. Comer AM, Perry CM, Figgitt DP. Caffeine citrate: a review of its use in apnoea of prematurity. Paediatr Drugs. 2001;3(1):61-79.
20. Natarajan G, Botica ML, Thomas R, et al. Therapeutic drug monitoring for caffeine in preterm neonates: an unnecessary exercise? Pediatrics. 2007;119(5):936-40.
21. Bairam A, Boutroy MJ, Badonnel Y, et al. Theophylline versus caffeine: comparative effects in treatment of idiopathic apnea in the preterm infant. J Pediatr. 1987;110(4):636-9.
22. Brouard C, Moriette G, Murat I, et al. Comparative efficacy of theophylline and caffeine in the treatment of idiopathic apnea in premature infants. Am J Dis Child. 1985;139(7):698-700.
23. Fuglsang G, Nielsen K, Kjaer Nielsen L, et al. The effect of caffeine compared with theophylline in the treatment of idiopathic apnea in premature infants. Acta Paediatr Scand. 1989;78(5):786-8.
24. Scanlon JE, Chin KC, Morgan ME, et al. Caffeine or theophylline for neonatal apnoea? Arch Dis Child. 1992;67(4 Spec No):425-8.
25. Kumar SP, Mehta PN, Bradley BS, Ezhuthachan SG. Documented monitoring (DM) shows theophylline (T) to be more effective than caffeine (C) in prematurity apnea (PA). Pediatr Res. 1992;31:208A.
26. Laubscher B, Greenough A, Dimitriou G. Comparative effects of theophylline and caffeine on respiratory function of prematurely born infants. Early Human Dev. 1998;50(2):185-92.
27. Patel RM, Leong T, Carlton DP, et al. Early caffeine therapy and clinical outcomes in extremely preterm infants. J Perinatol Off J Calif Perinatal Assoc. 2013;33(2):134-40.
28. Davis PG, Schmidt B, Roberts RS, et al. Caffeine for apnea of prematurity trial: benefits may vary in subgroups. J Pediatr. 2010;156(3):382-7.
29. Skouroliakou M, Bacopoulou F, Markantonis SL. Caffeine versus theophylline for apnea of prematurity: a randomised controlled trial. J Paediatr Child Health. 2009;45(10):587-92.
30. Bucher HU, Duc G. Does caffeine prevent hypoxaemic episodes in premature infants? A randomized controlled trial. Eur J Pediatr. 1988;147(3):288-91.
31. Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity. N Engl J Med. 2006;354(20):2112-21.
32. Schmidt B, Roberts RS, Davis P, et al. Long-term effects of caffeine therapy for apnea of prematurity. N Engl J Med. 2007;357(19):1893-902.
33. Dukhovny D, Lorch SA, Schmidt B, et al. Economic evaluation of caffeine for apnea of prematurity. Pediatrics. 2011;127(1):e146-55.
34. McGowan JD, Altman RE, Kanto WP Jr. Neonatal withdrawal symptoms after chronic maternal ingestion of caffeine. South Med J. 1988;81(9):1092-4.
35. Banner W Jr, Czajka PA. Acute caffeine overdose in the neonate. Am J Dis Child. 1980;134(5):495-8.
36. Kulkarni PB, Dorand RD. Caffeine toxicity in a neonate. Pediatrics. 1979;64(2):254-5.
37. Gray PH, Flenady VJ, Charles BG, et al. Caffeine citrate for very preterm infants: effects on development, temperament and behaviour. J Paediatr Child Health. 2011;47(4):167-72.
38. Hoecker C, Nelle M, Poeschl J, et al. Caffeine impairs cerebral and intestinal blood flow velocity in preterm infants. Pediatrics. 2002;109(5):784-7.
39. Saliba E, Autret E, Gold F, et al. Effect of caffeine on cerebral blood flow velocity in preterm infants. Biol Neonate. 1989;56(4):198-203.
40. Hoecker C, Nelle M, Beedgen B, et al. Effects of a divided high loading dose of caffeine on circulatory variables in preterm infants. Arch Dis Child Fetal Neonatal Ed. 2006;91(1):F61-4.
41. Hascoet JM, Hamon I, Boutroy MJ. Risks and benefits of therapies for apnoea in premature infants. Drug Saf. 2000;23(5):363-79.
42. Lowry JA, Jarrett RV, Wasserman G, et al. Theophylline toxicokinetics in premature newborns. Arch Pediatr Adolesc Med. 2001;155(8):934-9.
43. Aden U. Methylxanthines during pregnancy and early postnatal life. Handb Exp Pharmacol. 2011;200:373-89.
44. Carnielli VP, Verlato G, Benini F, et al. Metabolic and respiratory effects of theophylline in the preterm infant. Arch Dis Child Fetal Neonatal Ed. 2000;83(1):F39-43.
45. Bauer J, Maier K, Linderkamp O, et al. Effect of caffeine on oxygen consumption and metabolic rate in very low birth weight infants with idiopathic apnea. Pediatrics. 2001;107(4):660-3.
46. Skopnik H, Koch G, Heimann G. Effect of methylxanthines on periodic respiration and acid gastroesophageal reflux in newborn infants [in German]. Monatsschr Kinderheilkd. 1990;138(3):123-7.
47. Kearns GL, Abdel-Rahman SM, Alander SW, et al. Developmental pharmacology: drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349(12):1157-67.
48. Aranda JV, Collinge JM, Zinman R, et al. Maturation of caffeine elimination in infancy. Arch Dis Child. 1979;54(12):946-9.
49. Arant BS Jr. Developmental patterns of renal functional maturation compared in the human neonate. J Pediatr. 1978;92(5):705-12.
50. van den Anker JN, Schoemaker RC, Hop WC, et al. Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age. Clin Pharmacol Ther. 1995;58(6):650-9.
51. Bhatia J. Current options in the management of apnea of prematurity. Clin Pediatr. 2000;39(6):327-36.
52. Ramanathan R, Corwin MJ, Hunt CE, et al. Cardiorespiratory events recorded on home monitors: comparison of healthy infants with those at increased risk for SIDS. JAMA. 2001;285(17):2199-207.
53. Rosen CL, Glaze DG, Frost JD Jr. Home monitor follow-up of persistent apnea and bradycardia in preterm infants. Am J Dis Child. 1986;140(6):547-50.
54. Di Fiore JM, Arko MK, Miller MJ, et al. Cardiorespiratory events in preterm infants referred for apnea monitoring studies. Pediatrics. 2001;108(6):1304-8.
55. Lee TC, Charles B, Steer P, et al. Population pharmacokinetics of intravenous caffeine in neonates with apnea of prematurity. Clin Pharmacol Ther. 1997;61(6):628-40.
56. Tayman C, Rayyan M, Allegaert K. Neonatal pharmacology: extensive interindividual variability despite limited size. J Pediatr Pharmacol Ther. 2011;16(3):170-84.
57. Jonkman JH, Upton RA. Pharmacokinetic drug interactions with theophylline. Clin Pharmacokinet. 1984;9(4):309-34.
58. Healy DP, Polk RE, Kanawati L, et al. Interaction between oral ciprofloxacin and caffeine in normal volunteers. Antimicrob Agents Chemother. 1989;33(4):474-8.
59. Holstege A, Staiger M, Haag K, et al. Correlation of caffeine elimination and Child's classification in liver cirrhosis. Klinische Wochenschrift. 1989;67(1):6-15.
60. Piafsky KM, Sitar DS, Rangno RE, et al. Theophylline disposition in patients with hepatic cirrhosis. N Engl J Med. 1977;296(26):1495-7.
61. Leon AE, Michienzi K, Ma CX, et al. Serum caffeine concentrations in preterm neonates. Am J Perinatol. 2007;24(1):39-47.
62. Aranda JV, Grondin D, Sasyniuk BI. Pharmacologic considerations in the therapy of neonatal apnea. Pediatr Clin North Am. 1981;28(1):113-33.
63. Pesce AJ, Rashkin M, Kotagal U. Standards of laboratory practice: theophylline and caffeine monitoring. National Academy of Clinical Biochemistry. Clin Chem. 1998;44(5):1124-8.
64. Hivert V, Bécas-Garro MP. Lists of medicinal products for rare diseases in Europe. Orphanet Report Series, Orphan Drugs Collection. October 2013.
65. Henderson-Smart DJ, De Paoli AG. Prophylactic methylxanthine for prevention of apnoea in preterm infants. Cochrane Database Syst Rev. 2010(12):CD000432.